Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence:patient-reported outcome at 4 weeks
Objective improvement following intradetrusor injections of botulinum neurotoxin type A (BoNTA) is well documented. Although patient-related outcome measures are highly recommended for monitoring overactive bladder symptoms, no study before has dealt with the question of patient-reported complete continence after BoNTA treatment using validated questionnaires
